Risk adjusted net present value: What is the current valuation of Avidity Biosciences’s AOC-1020?

AOC-1020 is an antisense rnai oligonucleotide commercialized by Avidity Biosciences, with a leading Phase II program in Facioscapulohumeral Muscular Dystrophy (FSHD).

Subsense Emerges from Stealth with $17M to Develop Non-Surgical Brain-Computer Interface

What You Should Know: – Subsense, Inc., a pioneering neurotechnology company announced its official launch and the closing of a $17 million seed funding round

February 18, 2025

It’s time to rethink the Medicare annual wellness visit

In 2011, the Centers for Medicare and Medicaid Services created the annual wellness visit (AWV), a new visit type with no cost to Medicare patients,

December 12, 2023

ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission

SAN DIEGO — Autologous stem-cell transplantation (ASCT) led to improved outcomes as compared with CAR T-cell therapy for patients with relapsed large B-cell lymphoma (LBCL)

December 11, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.